309 results on '"Dómine M"'
Search Results
2. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
3. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
4. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
5. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
6. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials
7. P1.01-04 Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients
8. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
9. P2.16-02 Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial
10. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
11. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
12. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study
13. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
14. 20370. CRANIECTOMÍA DESCOMPRESIVA EN HEMORRAGIA INTRACEREBRAL PROFUNDA: APLICABILIDAD Y RESULTADOS DE LOS CRITERIOS DEL ENSAYO SWITCH EN UNA COHORTE POBLACIONAL DE CATALUÑA
15. 20188. PATRÓN DINÁMICO DE NEUROIMAGEN Y CARACTERÍSTICAS CLÍNICAS EN UNA SERIE DE CASOS DE PACIENTES CON EMBOLIA GRASA CEREBRAL
16. Piecewise Linear Analysis
17. Piecewise Linear Modeling of Electrical Circuits
18. Multiple Solutions
19. Solution Algorithms
20. The State Model of a Piecewise Linear Network
21. Piecewise Linear Model Descriptions
22. P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
23. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
24. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
25. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study
26. Reducing Substrate Bounce in CMOS RF-Circuitry : On the use of guard rings
27. EP.06G.20 Advanced Squamous Cell Lung Carcinoma in Never Smokers: A Different Entity? Analysis from the Thoracic Tumor Registry in Spain (RTT)
28. EP.13D.09 Characteristics and Survival in Never-Smoking Small Cell Lung Cancer Cases an Analysis from the Thoracic Tumor Registry
29. EP.01A.05 Analysis of Diagnostic Delay and Its Impact on Survival in Lung Cancer Cases. Results from the Spanish Thoracic Tumor Registry
30. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
31. MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)
32. Mixed-Mode Telecom Design
33. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
34. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
35. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
36. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
37. Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary
38. MA14.12 Characterization of Sexual Dysfunction in Patients with Lung Cancer Undergoing Oncological Management: Results from the LUDICAS Study
39. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used
40. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
41. 2024P Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
42. 2016P The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
43. 1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
44. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
45. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial
46. LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
47. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
48. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
49. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain
50. MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.